These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22949145)

  • 1. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
    Boikos SA; Hammers HJ
    J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
    Adhikaree J; Newby Y; Sundar S
    BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.
    Massaro AM
    Cancer Pract; 2002; 10(4):219-21. PubMed ID: 12100107
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
    Freeman A; El-Amm J; Aragon-Ching JB
    Clin Genitourin Cancer; 2013 Dec; 11(4):e24-6. PubMed ID: 24007982
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypercalcemia upon recurrence of renal cell carcinoma producing parathyroid hormone-related protein.
    Ueno M; Tokonabe S; Kuroda I; Tsukamoto T; Deguchi N
    Scand J Urol Nephrol; 2003; 37(3):265-8. PubMed ID: 12775288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Refractory hypercalcemia in patient with lung cancer].
    Grzywacz A; Dziuk M; Niemczyk S
    Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?
    Bech A; Essink G; de Boer H
    Neth J Med; 2012 Jun; 70(5):250-1. PubMed ID: 22744931
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose of bisphosphonate for hypercalcaemia of malignancy.
    Morton AR; Friefeld J; Halperin F
    Lancet; 1990 Jun; 335(8703):1469-70. PubMed ID: 1972245
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.
    Diel IJ; Bergner R
    Oncologist; 2005 Jan; 10(1):82-3; author reply 84-7. PubMed ID: 15632256
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma.
    Michaelson MD; Rosenthal DI; Smith MR
    J Clin Oncol; 2004 Oct; 22(20):4233-4. PubMed ID: 15483039
    [No Abstract]   [Full Text] [Related]  

  • 13. The issue of renal safety of zoledronic acid from a nephrologist's point of view.
    Balla J
    Oncologist; 2005 May; 10(5):306-8; author reply 311-2. PubMed ID: 15851781
    [No Abstract]   [Full Text] [Related]  

  • 14. [Results of using Aredia for hypercalcemia in oncology patients].
    Lichinitser MR; Vyshinskaia GV; Kupchan DZ; Liubimova NV
    Ter Arkh; 1993; 65(9):80-1. PubMed ID: 8303606
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.
    Kurabayashi A; Inoue K; Fukuhara H; Karashima T; Fukata S; Kawada C; Shuin T; Furihata M
    Cancer Sci; 2015 Aug; 106(8):1092-9. PubMed ID: 26041278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
    Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
    Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
    J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypercalcemia and bone resorption in malignancy.
    Walls J; Bundred N; Howell A
    Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Adhikaree J; Newby Y; Sundar S
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Tsuda M; Ishiguro H; Yano I; Toi M
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.